Skip to main content

Table 2 Summarization of neurological status and details pertaining to COVID-19 symptomatology and behavior of suspected or confirmed COVID-19 cohort

From: Impact of COVID-19 pandemic in natural course of Moyamoya Angiopathy: an experience from tertiary-care-center in India

  Child (n = 11) (%) Adult (n = 3) (%) Total (n = 14) (%)
1. Symptomatology related to COVID-19
 (a) Fever 100 100 100
 (b) Others
  I. Sore throat 90.9 66.7 85.7
  II. Dry cough 45.5 100 57.1
  III. Dyspnea 0 0 0
  IV. Pain abdomen 9.1 0 7.1
  V. Diarrhea 27.3 33.3 28.6
  VI. Loss of smell 36.4 100 50.0
  VII. Loss of taste 18.2 100 35.7
  VIII. Headache 27.3 100 42.9
  IX. Red eyes 0 0 0
  X. Myalgia 81.8 100 88.9
  XI. Skin rashes 0 0 0
2. Involvement of family members 63.6 66.7 64.4
3. History of contact with COVID-19 patients 63.6 100 71.4
4. Travel history 0 66.7 14.3
5. Hospitalization 9.1 0 7.1
6. Residence in containment zone 100 100 100
7. Co-morbidities
 (a) Hypertension 0 66.7 14.3
 (b) Type II Diabetes Mellitus 0 33.3 7.1
 (c) Hypothyroidism 0 0 0
 (d) Renal dysfunction 0 0 0
 (e) Cardiac dysfunction 0 0 0
 (f) Liver dysfunction 0 0 0
 (g) Hematological dysfunction 9.1 0 7.1
8. Neurological symptom (worsening or new onset)
 (a) Fixed motor weakness 9.1 0 7.1
 (b) Seizure 18.2 0 14.3
 (c) Headache 9.1 33.3 14.3
 (d) Transient ischemic attack 45.5 0 35.7
 (e) Cognitive and behavioral symptoms 0 0 0
 (f) Visual symptoms 0 0 0
 (g) Extra-pyamidal symptoms 0 0 0
  1. n: Number